Integrated Use of Autosomal Dominant Polycystic Kidney Disease Prediction Tools for Risk Prognostication

被引:1
|
作者
Wolff, Constantin A. [1 ]
Aiello, Valeria [2 ]
Elhassan, Elhussein A. E. [3 ,4 ]
Cristalli, Carlotta [5 ]
Lerario, Sarah [2 ]
Paccapelo, Alexandro [6 ]
Ciurli, Francesca [2 ]
Montanari, Francesca [5 ]
Conti, Amalia [5 ]
Benson, Katherine [7 ]
Seri, Marco [5 ]
Brigl, Carolin B. [1 ]
Muenster, Julia S. [1 ]
Sciascia, Nicola [8 ]
Kursch, Sebastian [9 ]
de Fallois, Jonathan [9 ]
La Manna, Gaetano [2 ,10 ]
Eckardt, Kai-Uwe [1 ]
Rank, Nina [1 ]
Popp, Bernt [11 ]
Schoenauer, Ria [1 ]
Conlon, Peter J. [3 ,4 ]
Capelli, Irene [2 ,10 ]
Halbritter, Jan [1 ]
机构
[1] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany
[2] IRCCS Azienda Osped Univ Bologna, Nephrol Dialysis & Kidney Transplant Unit, Bologna, Italy
[3] Beaumont Hosp, Dept Nephrol & Transplantat, Dublin, Ireland
[4] Royal Coll Surgeons Ireland, Dept Med, Dublin, Ireland
[5] IRCCS Azienda Osped Univ Bologna, Med Genet Unit, Bologna, Italy
[6] IRCCS Azienda Osped Univ ia Bologna, Res & Innovat Unit, Bologna, Italy
[7] Royal Coll Surg, Sch Pharm & Biomol Sci, Dublin, Ireland
[8] Univ Bologna, Dept Med & Surg Sci DIMEC, Alma Mater Studiorum, Bologna, Italy
[9] IRCCS Azienda Osped Univ Bologna, Oncohematol & Emergency Radiol Unit, Pediat & Adult CardioThorac & Vasc, Bologna, Italy
[10] Univ Hosp Leipzig, Div Nephrol, Leipzig, Germany
[11] Berlin Inst Hlth, Einstein Ctr Neurosci Berlin, D-10117 Berlin, Germany
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2025年 / 20卷 / 03期
关键词
ADPKD; CKD; cystic kidney; ESKD; gene expression; kidney volume; polycystic kidney disease; progression of renal failure; cystic kidney disease; genetic diseases and development; VOLUME; PROGRESSION; TOLVAPTAN; ADPKD;
D O I
10.2215/CJN.0000000625
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. Specific treatment is indicated on observed or predicted rapid progression. For the latter, risk stratification tools have been developed independently based on either total kidney volume or genotyping as well as clinical variables. This study aimed to improve risk prediction by combining both imaging and clinical-genetic scores. Methods We conducted a retrospective multicenter cohort study of 468 patients diagnosed with autosomal dominant polycystic kidney disease. Clinical, imaging, and genetic data were analyzed for risk prediction. We defined rapid disease progression as an eGFR slope >= 3 ml/min per 1.73 m(2) per year over 2 years, Mayo imaging classification (MIC) 1D-1E, or a predicting renal outcome in polycystic kidney disease (PROPKD) score of >= 7 points. Using MIC, PROPKD, and rare exome variant ensemble learner scores, several combined models were designed to develop a new classification with improved risk stratification. Primary endpoints were the development of advanced CKD stages G4-G5, longitudinal changes in eGFR, and clinical variables such as hypertension or urological events. Statistically, logistic regression, survival, receiver operating characteristic analyses, linear mixed models, and Cox proportional hazards models were used. Results PKD1-genotype (P < 0.001), MIC class 1E (P < 0.001), early-onset hypertension (P < 0.001), and early-onset urological events (P = 0.003) correlated best with rapid progression in multivariable analysis. While the MIC showed satisfactory specificity (77%), the PROPKD was more sensitive (59%). Among individuals with an intermediate risk in one of the scores, integration of the other score (combined scoring) allowed for more accurate stratification. Conclusions The combined use of both risk scores was associated with higher ability to identify rapid progressors and resulted in a better stratification, notably among intermediate risk patients.
引用
收藏
页码:397 / 409
页数:13
相关论文
共 50 条
  • [21] The role of PPARα in autosomal dominant polycystic kidney disease
    Lakhia, Ronak
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (04): : 432 - 438
  • [22] Drug repurposing in autosomal dominant polycystic kidney disease
    Zhou, Julie Xia
    Torres, Vicente E.
    KIDNEY INTERNATIONAL, 2023, 103 (05) : 859 - 871
  • [23] Targeted Therapies for Autosomal Dominant Polycystic Kidney Disease
    Stayner, Cherie
    Brooke, Darby G.
    Bates, Michael
    Eccles, Michael R.
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (17) : 3081 - 3102
  • [24] Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
    Walz, Gerd
    Budde, Klemens
    Mannaa, Marwan
    Nuernberger, Jens
    Wanner, Christoph
    Sommerer, Claudia
    Kunzendorf, Ulrich
    Banas, Bernhard
    Hoerl, Walter H.
    Obermueller, Nicholas
    Arns, Wolfgang
    Pavenstaedt, Hermann
    Gaedeke, Jens
    Buechert, Martin
    May, Christoph
    Gschaidmeier, Harald
    Kramer, Stefan
    Eckardt, Kai-Uwe
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09): : 830 - 840
  • [25] Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update
    Gittus, Matt
    Haley, Helen
    Harris, Tess
    Borrows, Sarah
    Padmanabhan, Neal
    Gale, Danny
    Simms, Roslyn
    Williams, Terri
    Acquaye, Aaron
    Wong, Alisa
    Chan, Melanie
    Lee, Eduardo
    Ong, Albert C. M.
    BMC NEPHROLOGY, 2025, 26 (01)
  • [26] MRI in autosomal dominant polycystic kidney disease
    Zhang, Weiguo
    Blumenfeld, Jon D.
    Prince, Martin R.
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2019, 50 (01) : 41 - 51
  • [27] Treatment of autosomal dominant polycystic kidney disease
    Torra, Roser
    MEDICINA CLINICA, 2014, 142 (02): : 73 - 79
  • [28] Autosomal dominant polycystic kidney disease in Colombia
    Camargo, Jessica T. T.
    Gonzalez, Camilo A.
    Herrera, Lina
    Yomayusa-Gonzalez, Nancy
    Ibanez, Milciades
    Valbuena-Garcia, Ana M. M.
    Acuna-Merchan, Lizbeth
    BMC NEPHROLOGY, 2023, 24 (01)
  • [29] Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease
    Spithoven, Edwin M.
    van Gastel, Maatje D. A.
    Messchendorp, A. Lianne
    Casteleijn, Niek F.
    Drenth, Joost P. H.
    Gaillard, Carlo A.
    de Fijter, Johan W.
    Meijer, Esther
    Peters, Dorien J. M.
    Kappert, Peter
    Renken, Remco J.
    Visser, Folkert W.
    Wetzels, Jack F. M.
    Zietse, Robert
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2015, 66 (05) : 792 - 801
  • [30] Kidney Stone Disease and Progression Risk in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of OVERTURE
    Gitomer, Berenice Y.
    Chonchol, Michel
    Zhou, Xiaolei
    Garbinsky, Diana
    Wang, Jinyi
    Nunna, Sasikiran
    Fernandes, Ancilla W.
    Oberdhan, Dorothee
    KIDNEY360, 2024, 5 (09): : 1364 - 1366